

STUDENT IMMUNIZATION RECORD

Semester:	FALL:				
SPRING:					
SUMMER:					

FTI	JRN	IMI	JUN17	ATION	FORM	TO:

lease PRINT or TYPE all information <i>P: (845) 341-48</i>			J., IV	1iddletown, NY 10940			
NAME:							
LAST NAME			FIRST NAM	IE .		MIDDLE INITIAL	
ADDRESS:				CITY		ZIP	
					E:		
NVC Dublic Health law states that all	students n	aust most	the feller				
NYS Public Health law states that all IENINGITIS RESPONSE (COMPLETE BY STUDENT/PAR			-	-			
Check a	appropria	te box a	nd sign b	elow			
I have/my child has:							
[] had the meningococcal meningitis immunizat							
DATE RECEIVED:	(attach Mo	edical Dod	cumentation)			
[] read, or had explained to me, the information	n (see reve	rse side) r	egarding ı	meningococcal Menin	gitis diseas	se. I understand the risl	
of not receiving the vaccine. I have decided t	hat I (my c	hild) WILL	. NOT obt	ain immunization aga	inst Menin	gitis disease at this time	
SIGNED:		_DATE					
o be completed by Health Care Professional (MI	DOSE DOSE	Dose	Dose	Disease History	Titer	Titer Result*	
IMMUNIZATION/DISEASE	#1	#2	#3	(Medically	Date	Attach ALL	
REQUIRED:	Date	Date	Date	Documented)		Laboratory Results	
MMR (Measles, Mumps, Rubella) 2 Doses required <u>ON</u>				•		•	
or AFTER 12 months of age. The second MMR vaccine							
must be 30 days after the first vaccine. MMR							
requirement is only for those born on or after 01/01/57.							
After 1/1/68 – vaccines must be "LIVE"							
OR				Disease Date:	MD Signa	ature:	
MEASLES (Rubeola) 2 Doses REQUIRED							
				Disease Date:	MD Signa	ature:	
MUMPS 1 Dose REQUIRED							
				Disease Date:	MD Signa	ature:	
RUBELLA (German Measles) 1 Dose REQUIRED					- 0		
ROBELLA (German Measies) 1 2032 REQUIRED							
ADDITIONAL RECOMMENDED IMMUNIZATIONS							
TD (within last 10 years)							
The first to the f				1			
TDap (within last 10 years)							
HEPATITIS "B" – required 3 doses for all students or							
attach lab report showing evidence of immunity							
(Hep.B Antibody)							
				Disease Date:	MD Sigr	nature:	
VARICELLA (Chickenpox) or (Varicella Titer-attach a							
copy of lab report) Recommended if you are not immune							
All equivocal results require an additional vaccine.							
ovider Name (printed):			PROVII	DER STAMP:		For Office Use Only	
ovider Signature:						rdnc_np_nn_	
one Number:						ter Sent tion needed	
une muniber.					1 1	riewer	
					1 1		



Orange County Community College MENINGOCOCCAL MENINGITIS FACT SHEET

WHAT IS MENINGOCOCCAL MENINGITIS? Meningococcal disease is a severe bacterial infection of the bloodstream or meninges (a thin lining covering the brain and spinal cord). It is a relatively rare disease and usually occurs as a single isolated event. Clusters of cases or outbreaks are rare in the United States.

HOW IS THE GERM MENINGOCOCCUS SPREAD? Meningococcal disease is transmitted through the air via droplets of respiratory secretions and direct contact with an infected person. Direct contact, for these purposes, is defined as oral contact with shared items such as cigarettes or drinking glasses or through intimate contact such as kissing. Although anyone can come in contact with the bacteria that causes meningococcal disease, data also indicates certain social behaviors, such as exposure to passive and active smoking, bar patronage, and excessive alcohol consumption, may put students at increased risk for the disease. Patients with respiratory infections, compromised immunity, those in close contact to a known case, and travelers to endemic areas of the world are also at increased risk.

WHAT ARE THE SYMPTOMS? The early symptoms usually associated with meningococcal disease include fever, severe headache, stiff neck, rash, nausea, vomiting, and lethargy, and may resemble the flu. Because the disease progresses rapidly, often in as little as 12 hours, students are urged to seek medical care immediately if they experience two or more of these symptoms concurrently. The disease is occasionally fatal.

HOW SOON DO THE SYMPTOMS APPEAR? The symptoms may appear two to 10 days after exposure, but usually within five days.

WHAT IS THE TREATMENT FOR MENINGOCOCCAL DISEASE? Antibiotics, such as penicillin G or ceftriaxone, can be used to treat people with meningococcal disease.

SHOULD PEOPLE WHO HAVE BEEN IN CONTACT WITH A DIAGNOSED CASE OF MENINGOCOCCAL MENINGITIS BE

TREATED? Only people who have been in close contact (household members, intimate contacts, health care personnel performing mouth-to-mouth resuscitation, day care center playmates, etc.) need to be considered for preventive treatment. Such people are usually advised to obtain a prescription for a special antibiotic (either rifampin, ciprofloxacin or ceftriaxone) from their physician. Casual contact as might occur in a regular classroom, office or factory setting is not usually significant enough to cause concern.

IS THERE A VACCINE TO PREVENT MENINGOCOCCAL MENINGITIS? Presently, there is a vaccine that will protect against some of the strains of meningococcus. It is recommended in outbreak situations, and for those traveling to areas of the world where high rates of the disease are known to occur. For some college students, such as freshman living in dormitories, there is a modestly increased risk of meningococcal disease; students and parents should be educated about meningococcal disease and the availability of a safe and effective vaccine.

HOW EFFECTIVE IS THE VACCINE? The meningococcal vaccine has been shown to provide protection against the most common strains of the disease, including serogroups A, C, Y and W-135. The vaccine has shown to be 85 to 100 percent effective in serogroups A and C in older children and adults.

IS THE VACCINE SAFE? ARE THERE ADVERSE SIDE EFFECTS TO THE VACCINE? The vaccine is very safe and adverse reactions are mild and infrequent, consisting primarily of redness and pain at the site of injection lasting up to two days.

WHAT IS THE DURATION OF PROTECTION? The duration of the Menomune meningococcal vaccine is approximately three to five years. The Menactra vaccine may last up to ten years. The duration of protection from the Menveo vaccine, introduced in 2010, is not known.

COST AND AVAILABILITY –Vaccine cost is \$75 to \$110, and is available from your health care provider or the Department of Health. Call 291-2369 to schedule an appointment with the Department of Health.

August 2003. Source: New York State Department of Health Website (Revised 2003) and the American College Health Association Website.